Ключевые слова:
qandli diabet, yiringli-nekrotik jarayonlar, gemodinamik monitoring, NT-proBNP, yurak indeksi, yallig‘lanish markerlari.Библиографические ссылки
Лилли, С.Л. Патофизиология сердечно-сосудистой системы. Москва: Лаборатория знания, 2021. С. 337–375.
Марино, П.Л. Интенсивная терапия. Москва: ГЭОТАР-Медиа, 2023. С. 287–309.
Сапичева, Ю.Ю., Кассиль, В.Л. Интенсивная терапия в клинической практике. Москва: МЕДпресс-информ, 2015. С. 188–189.
American Diabetes Association. Standards of Medical Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl. 1):S1-S250.
World Health Organization. Global Report on Diabetes. World Health Organization; 2016.
Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-167.
Januzzi JL, Chen-Tournoux AA, Christenson RH. The evolution of NT-proBNP as a biomarker for heart failure. Clin Chem. 2019;65(10):1217-1227.
McCullough PA, Hollander JE, Nowak RM, et al. Uncovering heart failure in patients with a history of diabetes: the role of NT-proBNP. Rev Cardiovasc Med. 2003;4(Suppl. 7):S10-S17.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-2200.
McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012;33(14):1787-1847.
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure. J Am Coll Cardiol. 2013;62(16):e147-e239.
Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263-271.
Krum H, Gilbert RE. Demographics and concomitant disorders in heart failure. Lancet. 2003;362(9378):147-158